Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases, has appointed Kevin Tyler Sprott, PhD, as Chief Operating Officer.

“Peptone is poised to take a significant step forward in our drug discovery and development journey as we leverage the power of experimental physics, supported by AI-driven protein dynamics modelling and innovative technologies like HDX-MS, while also fostering strategic partnerships that amplify our ability to identify and generate novel IDP-targeted therapies across a variety of therapeutic fields,” said Kamil Tamiola, PhD, CEO of Peptone. “Kevin’s proven track record and blend of experience in both drug discovery and operational excellence are valuable assets for Peptone as we build our team for intentional growth and progress.”

About Dr. Kevin Tyler Sprott

Sprott previously founded and served as Chief Operations Officer of Stablix Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality. Throughout his career, he has played a vital role in the development of more than 10 INDs and clinical-stage assets across several leading companies, including Millennium, Ironwood Pharma, Verastem Oncology, Syros Pharmaceuticals, Ventus/SMOC Therapeutics, and Avilar Therapeutics.

Sprott’s contributions to the field include over 35 patents and provisional applications, as well as more than 40 manuscripts and presentations on small molecule drug discovery. He earned a Ph.D. in Organic Chemistry from the University of Kansas and completed postdoctoral research under Nobel laureate E.J. Corey at Harvard University.

“As someone who has spent my career pursuing previously elusive druggable targets, this opportunity is incredibly exciting. For decades, medicinal chemistry has been unable to successfully target IDPs, and Peptone’s data-driven approach unlocks an enormous potential to address diseases with significant unmet need,” said Sprott.